UPLOAD Filing
Ernexa Therapeutics Inc.
Date: March 20, 2026 · CIK: 0000748592 · Accession: 0000000000-26-002839
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-294307
Letter
March 20, 2026 Sanjeev Luther President and Chief Executive Officer Ernexa Therapeutics Inc. 1035 Cambridge Street, Suite 18A Cambridge, MA 02141 Re:Ernexa Therapeutics Inc. Registration Statement on Form S-3 Filed March 16, 2026 File No. 333-294307 Dear Sanjeev Luther: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Lawrence Metelitsa, Esq.
Show Raw Text
March 20, 2026
Sanjeev Luther
President and Chief Executive Officer
Ernexa Therapeutics Inc.
1035 Cambridge Street, Suite 18A
Cambridge, MA 02141
Re:Ernexa Therapeutics Inc.
Registration Statement on Form S-3
Filed March 16, 2026
File No. 333-294307
Dear Sanjeev Luther:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Lawrence Metelitsa, Esq.